Skip to main content
. Author manuscript; available in PMC: 2021 Jan 15.
Published in final edited form as: Semin Hematol. 2020 Nov 17;57(4):185–193. doi: 10.1053/j.seminhematol.2020.11.003

Fig. 3.

Fig. 3.

Summary of the first-in-human ML NK cell clinical study. Relapsed or refractory AML patients were lymphodepleted with flu/cy, and then received allogeneic donor NK cells that were activated with IL-12, IL-15, and IL-18. Following transfer, memory-like differentiation and expansion occurs in vivo in the patient, providing a 2–3 week window of opportunity to attack and eliminate AML.